Breaking News Instant updates and real-time market news.

HRL

Hormel Foods

$36.46

0.01 (0.03%)

, KTOS

Kratos Defense

$10.43

0.05 (0.48%)

10:17
12/01/17
12/01
10:17
12/01/17
10:17

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hormel Foods (HRL) reinstated with an Overweight at Barclays. 2. Kratos Defense (KTOS) initiated with a Neutral at JPMorgan. 3. Portola Pharmaceuticals (PTLA) initiated with a Buy at Goldman Sachs. 4. Diamondback Energy (FANG) initiated with a Buy at Citi. 5. Booz Allen (BAH) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

HRL

Hormel Foods

$36.46

0.01 (0.03%)

KTOS

Kratos Defense

$10.43

0.05 (0.48%)

PTLA

Portola Pharmaceuticals

$50.75

2.25 (4.64%)

FANG

Diamondback Energy

$109.31

1.16 (1.07%)

BAH

Booz Allen

$38.70

0.01 (0.03%)

  • 04

    Dec

  • 14

    Dec

  • 02

    Feb

HRL Hormel Foods
$36.46

0.01 (0.03%)

12/01/17
LEHM
12/01/17
INITIATION
Target $40
LEHM
Overweight
Hormel Foods reinstated with an Overweight at Barclays
Barclays analyst Benjamin Theurer reinstated Hormel Foods with an Overweight rating and $40 price target. The analyst sees the company as "well positioned to perform solidly" despite industry headwinds.
11/03/17
MSCO
11/03/17
INITIATION
Target $26
MSCO
Underweight
Hormel Foods initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst John Colantuoni initiated coverage of the protein producers with a cautious view of the sector, as he sees the risk-reward skewed to the downside with supply/demand imbalances looming. He started Hormel Foods with an Underweight rating, as he expects flat EPS over FY18/FY19 given likely margin pressure in pork and heightened competition in packaged foods. He set a $26 price target on Hormel shares.
11/03/17
11/03/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. YogaWorks (YOGA) initiated with an Outperform at Imperial Capital. 2. IRIDEX (IRIX) resumed with a Buy at Roth Capital. 3. TE Connectivity (TEL) initiated with an Outperform at Baird. 4. Pilgrim's Pride (PPC), Sanderson Farms (SAFM), and Tyson Foods (TSN) were initiated with an Equal Weight at Morgan Stanley, while Hormel Foods (HRL) initiated with an Underweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/17
MSCO
11/22/17
NO CHANGE
Target $26
MSCO
Underweight
Hormel Foods 2018 guidance seems optimistic, says Morgan Stanley
Morgan Stanley analyst John Colantuoni said he sees Hormel Foods' guidance for low-single digit hog inflation as aggressive given capacity expansion and tough comparisons, leading him to view the company's initial 2018 outlook as optimistic. The analyst, who continues to view the stock's valuation premium to the Packaged Food group as unsustainable, maintains an Underweight rating and $26 price target on Hormel shares.
KTOS Kratos Defense
$10.43

0.05 (0.48%)

11/08/17
ADAM
11/08/17
NO CHANGE
Target $15
ADAM
Buy
Kratos Defense note offering a net positive, says Canaccord
Canaccord analyst Ken Herbert believes the Kratos Defense note offering is a net positive as it will enable the company to retire all of its current 2019 outstanding debt while providing the company with more than $100M of cash to invest in organic growth opportunities. The analyst said the next challenge will be for the company to demonstrate that the better than expected top-line outlook can translate into the EBITDA and free cash flow that he believes is possible. Herbert reiterated his Buy rating and $15 price target on Kratos Defense shares.
11/06/17
ADAM
11/06/17
NO CHANGE
Target $15
ADAM
Buy
Kratos Defense weakness attributed to capital raise speculation, says Canaccord
Canaccord analyst Ken Herbert noted Kratos Defense shares were weak following Q3 results as he heard a short reported had been circulating the company was planning to issue a convertible bond offering. Although he could not verify the existence of the report, he said management indicated they have no plans to issue any converts and the only planned balance sheet activity is its well-known debt refinance strategy that would cut about $100M of debt. Herbert reiterated his Buy rating and $15 price target on Kratos Defense shares.
11/01/17
ADAM
11/01/17
NO CHANGE
Target $15
ADAM
Buy
Kratos Defense report focus will be on backlog, says Canaccord
Canaccord analyst Ken Herbert previewed Kratos Defense's Q3 report and he expects the numbers to be in-line but for investors to focus on the company's backlog. Q2 showed a softer backlog due to the timing of awards so a step up is to be expected. The analyst does not expect guidance until the next quarterly call, but he views Kratos as a core holding for exposure to the defense budget cycle and specific areas of upside in unmanned systems, satellite communications, missile defense, and training. Herbert reiterated his Buy rating and $15 price target on Kratos Defense shares.
12/01/17
JPMS
12/01/17
INITIATION
Target $13
JPMS
Neutral
Kratos Defense initiated with a Neutral at JPMorgan
JPMorgan analyst Seth Seifman started Kratos Defense & Security Solutions with a Neutral rating and $13 price target. The analyst believes the recent share rally captures much of the upside from the company's growth and repaired balance sheet.
PTLA Portola Pharmaceuticals
$50.75

2.25 (4.64%)

09/19/17
SBSH
09/19/17
NO CHANGE
SBSH
Buy
Portola selloff on draft guidance 'red herring' a buying opportunity, says Citi
Citi analyst Yigal Nochomovitz attributes today's selloff in Portola Pharmaceuticals shares to controversy over the fact that the American Society of Hematology's draft recommendations argue against extended prophylaxis for VTE in acute medically ill patients. However, he points out that the document lacks any mention of Bevyxxa's status as FDA approved, which suggests the draft "needs to be revisited and/or is stale." The analyst concludes the draft was made prior to Bevyxxa approval and before the "many, many downstream publications" Portola has generated since then. Nochomovitz, who recommends investors buy the dip, keeps a Buy rating on Portola, which is down 7% in afternoon trading.
11/28/17
SBSH
11/28/17
NO CHANGE
SBSH
Citi adds Portola, removes PBF from 'Value Creators' List
Citi analyst Scott Chronert added Portola Pharmaceuticals (PTLA) and removed PBF Energy (PBF) from his firm's "Value Creators" SMID Focus List. The analyst views Portola as a "catalyst rich Biotech with M&A potential" and notes PBF shares are up 41% since the end of August.
12/01/17
GSCO
12/01/17
INITIATION
Target $75
GSCO
Buy
Portola Pharmaceuticals initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Dana Flanders started Portola Pharmaceuticals with a Buy rating and $75 price target. The analyst views the company's growth profile as attractive and sees potential upside from M&A.
09/20/17
FBCO
09/20/17
NO CHANGE
Target $70
FBCO
Outperform
Portola Pharmaceuticals selloff surprising, says Credit Suisse
Credit Suisse analyst Vamil Divan says he is surprised that Portola shares sold off about 8% on concerns that extended duration VTE prophylaxis for acute medically ill patients is not recommended in draft guidelines from the American Society of Hematology. The analyst believes the negative reaction is unwarranted, and reiterates an Outperform rating and $70 price target on the shares.
FANG Diamondback Energy
$109.31

1.16 (1.07%)

12/01/17
SBSH
12/01/17
INITIATION
Target $130
SBSH
Buy
Diamondback Energy initiated with a Buy at Citi
Citi analyst Robert Morris started Diamondback Energy with a Buy rating and $130 price target. The analyst sees the company delivering above-average cash flow growth per debt adjusted share through 2021 given its positions in the Midland Basin and "strong growth platform" in the Delaware Basin.
11/20/17
LEHM
11/20/17
UPGRADE
Target $137
LEHM
Overweight
Diamondback Energy upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Thomas Driscoll upgraded Diamondback Energy to Overweight and raised his price target for the shares to $137 from $121. The analyst also raised his industry view to Positive for the mid-cap Exploration & Production space and to Neutral for the large-cap space. He expects producers can capitalize on efficiency gains to deliver improved returns.
11/17/17
11/17/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Buffalo Wild Wings (BWLD) downgraded to Hold from Buy at Deutsche Bank with analyst Brett Levy saying the risk/reward is less favorable following reports of a potential takeover bid. 2. Williams-Sonoma (WSM) was downgraded to Reduce from Accumulate at Gordon Haskett and to Underweight from Overweight at JPMorgan. 3. Diamondback Energy (FANG) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst John Nelson citing the recent bounce in shares. 4. Time Inc. (TIME) downgraded to Hold from Buy at Gabelli with analyst Barry Lucas citing news Meredith submitted a bid of $17-$20 per share to acquire the company. 5. CarMax (KMX) downgraded to Hold from Buy at Deutsche Bank with analyst Rod Lache saying his acceleration in same store sales growth thesis has played out while comparisons become somewhat more challenging going forward. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/17/17
GSCO
11/17/17
DOWNGRADE
Target $118
GSCO
Buy
Diamondback Energy downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman analyst John Nelson removed Diamondback Energy from the Conviction Buy List citing the recent bounce in shares and maintained a Buy rating and $118 price target.
BAH Booz Allen
$38.70

0.01 (0.03%)

11/21/17
STFL
11/21/17
INITIATION
Target $46
STFL
Buy
Booz Allen resumed with a Buy at Stifel
Stifel analyst Joseph DeNardi resumed coverage of Booz Allen Hamilton with a Buy rating and $46 price target.
11/07/17
11/07/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UAA, UA) upgraded to Neutral from Negative at Susquehanna with analyst Sam Poser saying his downside thesis has played out. He now believes the downside is limited and the bar may have been set low enough to hit the reset button, although business will be challenging for some time. Poser lowered his price target to $11 from $15 on Under Armour shares. 2. Michael Kors (KORS) upgraded to Neutral from Sell at MKM Partners with analyst Roxanne Meyer saying the latest second quarter earnings show that the company has delivered on its strategies, reporting better first-half comps and improved gross margins. 3. AutoWeb (AUTO) upgraded to Outperform from Market Perform at Barrington with analyst Gary Prestopino saying he believes management has stabilized the business after its third quarter results were in-line and guidance for 2017 was maintained. 4. Las Vegas Sands (LVS) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Thomas Allen saying he now expects Macau gaming revenue to grow at a 10% compound annual growth rate through 2022 given China's transition to a high income economy, continued development and improving infrastructure. 5. Booz Allen (BAH) upgraded to Buy from Hold at Jefferies with analyst Sheila Kahyaoglu saying she views the post-earnings pullback in the shares as a buying opportunity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/17
JEFF
11/07/17
UPGRADE
Target $44
JEFF
Buy
Booz Allen upgraded to Buy from Hold at Jefferies
Jefferies analyst Sheila Kahyaoglu upgraded Booz Allen Hamilton to Buy and raised her price target for the shares to $44 from $36. The analyst views yesterday's post-earnings pullback in the shares as a buying opportunity. He views Booz Allen as undervalued given its "peer-leading revenue growth."
12/01/17
RHCO
12/01/17
INITIATION
Target $47
RHCO
Buy
Booz Allen initiated with a Buy at SunTrust
SunTrust analyst Tobey Sommer initiated Booz Allen with a Buy rating and a price target of $47, saying the company is a "sustainable market share gainer". Sommer says Booz Allen may post organic revenue growth that is 5-8 points faster than comparable firms, adding that higher growth is sustainable because of the company's "consulting heritage" and targeted hiring in high demand areas such as machine learning, platform cyber and directed energy.

TODAY'S FREE FLY STORIES

ADBE

Adobe

$175.00

-1.83 (-1.03%)

07:15
12/15/17
12/15
07:15
12/15/17
07:15
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIGL

Rigel Pharmaceuticals

$3.57

-0.15 (-4.03%)

07:14
12/15/17
12/15
07:14
12/15/17
07:14
Initiation
Rigel Pharmaceuticals initiated  »

Cantor sees FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

CRTO

Criteo

$24.42

-7.19 (-22.75%)

07:12
12/15/17
12/15
07:12
12/15/17
07:12
Downgrade
Criteo rating change  »

Criteo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$50.19

0.14 (0.28%)

07:11
12/15/17
12/15
07:11
12/15/17
07:11
Recommendations
Oracle analyst commentary  »

Oracle business momentum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIPR

Innovative Industrial Properties

$22.60

2.28 (11.22%)

07:10
12/15/17
12/15
07:10
12/15/17
07:10
Hot Stocks
Innovative Industrial Properties raises quarterly dividend to 25c per share »

Innovative Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOLX

Hologic

$42.96

-0.72 (-1.65%)

07:08
12/15/17
12/15
07:08
12/15/17
07:08
Recommendations
Hologic analyst commentary  »

Hologic positioned well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:07
12/15/17
12/15
07:07
12/15/17
07:07
Earnings
Performance Food Group sees FY18 adjusted EPS up 13%-18% »

For fiscal 2018, PFG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

TYME

Tyme Technologies

$3.30

0.05 (1.54%)

07:05
12/15/17
12/15
07:05
12/15/17
07:05
Initiation
Tyme Technologies initiated  »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

, SNY

Sanofi

$43.09

-0.83 (-1.89%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Alnylam announces lift of FDA clinical hold on Fitusiran »

Alnylam Pharmaceuticals…

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

SNY

Sanofi

$43.09

-0.83 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

, UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Upgrade
Under Armour; also tag UAA, Under Armour; also tag UA rating change  »

Under Armour upgraded to…

UA

Under Armour; also tag UAA

$12.45

0.09 (0.73%)

UAA

Under Armour; also tag UA

$13.82

0.2 (1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBA

Ritchie Bros.

$28.69

0.3 (1.06%)

07:04
12/15/17
12/15
07:04
12/15/17
07:04
Hot Stocks
Ritchie Bros. sess $50M+ of equipment in final Fort Worth, TX auction of 2017 »

This week Ritchie Bros.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$43.09

-0.83 (-1.89%)

, ALNY

Alnylam

$123.66

-1.2 (-0.96%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Sanofi says FDA lifts clinical hold on fitusiran »

Sanofi Genzyme, the…

SNY

Sanofi

$43.09

-0.83 (-1.89%)

ALNY

Alnylam

$123.66

-1.2 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

  • 02

    May

CROX

Crocs

$10.94

-0.34 (-3.01%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Upgrade
Crocs rating change  »

Crocs upgraded to Buy on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

  • 08

    Jan

ESNC

EnSync

$0.44

0.0663 (17.79%)

, CHTR

Charter

$328.68

-0.32 (-0.10%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
EnSync: Spectrum solar plus storage project commissioned in Hawaii »

EnSync (ESNC) announces…

ESNC

EnSync

$0.44

0.0663 (17.79%)

CHTR

Charter

$328.68

-0.32 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

PFGC

Performance Food Group

$30.55

-0.9 (-2.86%)

07:03
12/15/17
12/15
07:03
12/15/17
07:03
Hot Stocks
Performance Food Group appoints Jim Hope as CFO »

Performance Food Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

07:02
12/15/17
12/15
07:02
12/15/17
07:02
Hot Stocks
Aclaris Therapeutics receives FDA approval for Eskata topical solution, 40% »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

AER

AerCap

$52.12

-0.46 (-0.87%)

07:01
12/15/17
12/15
07:01
12/15/17
07:01
Recommendations
AerCap analyst commentary  »

AerCap book value can hit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$37.30

-0.75 (-1.97%)

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Recommendations
Q2 Holdings analyst commentary  »

Q2 Holdings has strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:00
12/15/17
12/15
07:00
12/15/17
07:00
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$6.82

-0.2 (-2.85%)

06:59
12/15/17
12/15
06:59
12/15/17
06:59
Downgrade
Fitbit rating change  »

Fitbit downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,174.80

10.61 (0.91%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Periodicals
Luxembourg appeals EU order to recover tax from Amazon, Reuters reports »

Luxembourg is appealing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

06:55
12/15/17
12/15
06:55
12/15/17
06:55
Hot Stocks
Breaking Hot Stocks news story on Aclaris Therapeutics »

Aclaris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Dec

GDX

Market Vector Gold Miners

$22.07

-0.09 (-0.41%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$110.57

2.96 (2.75%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Recommendations
Disney, 21st Century Fox analyst commentary  »

Disney price target…

DIS

Disney

$110.57

2.96 (2.75%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

GLD

SPDR Gold Trust

$118.93

-0.24 (-0.20%)

06:54
12/15/17
12/15
06:54
12/15/17
06:54
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.